Ann: Expanded Heart Protection Discovery for Zantrene, page-276

@RaceOncology

Hi Dr T. We've found that Zantrene is synergistic with Cafilzomib in a cell line H929. Is the synergy presumably due to FTO? And if this is the case, would a coformulation of Zan+Car as a synergistic drug mainly be relevant in Myeloma lines that are FTO sensitive?

Would this require a companion diagnostic for FTO level determination as well? Or would it be used mainly for cardioprotection and the synergy may/may not be important if a CDx isn't used?

I'm just trying to determine how a trial would be set up and what the end point would be for it.